Takeda Pharmaceutical's sales revenue products FY 2018

In fiscal year 2018, the leading product in terms of sales of the Japanese pharmaceutical company Takeda Pharmaceutical Co. was Entyvio, with a sales value of more than 269 billion Japanese yen. Entyvio is a prescription drug treating adult patients with ulcerative colitis and Crohn's disease.

Global major products' sales revenue of Takeda Pharmaceutical Co., Ltd. in fiscal year 2018

Product sales in billion Japanese yen
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
Exclusive Premium statistic

You need a Single Account for unlimited access.

  • Full access to 1m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Single Account

only $59 / month *
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$708 / Year

Show detailed source information?
Register for free
Already a member?
Log in
Source

Release date

September 2019

Region

Worldwide, Japan

Survey time period

fiscal year 2018; the company’s fiscal year starts on April 1 of the stated year and ends on March 31 of the following year

Supplementary notes

1 Japanese yen equals 0.00943 U.S. dollars or 0.00862 euros as of September 2019. The source does not provide an exact publication date. Date given here is the day of data access.

Statista Accounts: Access All Statistics. Starting from $708 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account!

Single Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references

$59 / Month *

Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract.
   Prices do not include sales tax.

Statistics on "Pharmaceutical trends in Europe"

Statista Accounts: Access All Statistics. Starting from $708 / Year
Learn more about how Statista can support your business.